Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lumos Pharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
LUMO
Nasdaq
8731
https://lumos-pharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lumos Pharma Inc
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
- Apr 18th, 2024 8:05 pm
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
- Mar 20th, 2024 12:00 pm
Lumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Mar 10th, 2024 12:31 pm
Lumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call Transcript
- Mar 8th, 2024 7:06 pm
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
- Mar 7th, 2024 9:01 pm
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
- Feb 26th, 2024 2:00 pm
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
- Feb 5th, 2024 9:05 pm
Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth?
- Feb 5th, 2024 5:24 pm
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
- Jan 4th, 2024 9:05 pm
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
- Nov 21st, 2023 9:15 pm
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
- Nov 20th, 2023 9:05 pm
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
- Nov 7th, 2023 9:35 pm
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
- Nov 7th, 2023 9:01 pm
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
- Sep 26th, 2023 1:00 pm
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
- Sep 14th, 2023 12:00 pm
Lumos Pharma Announces Participation in Investor Conferences in September
- Sep 7th, 2023 8:34 pm
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
- Aug 22nd, 2023 1:00 pm
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
- Aug 9th, 2023 8:01 pm
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
- Jul 26th, 2023 1:00 pm
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
- Jul 12th, 2023 12:00 pm
Scroll